Health technology assessment

CCOHTA] Canadian Coordinating Office for Health Technology Assessment (1997). Selective Serotonin Re-uptake Inhibitors (SSRIs) for Major DepressionyVdJxll The Cost-... [Pg.52]

Claxton K., L. GinneUy, M. Sculpher, Z. Philips, and S. Palmer. 2004. A Pilot Study on the Use of Decision Theory and Value of Information Analysis as Past of the National Health Service Technology Assessment Programme. Health Technology Assessment 8(31) (whole issue). [Pg.296]

Sculpher, M. J., F. S. Pang, A. Manca, M. F. Drummond, S. Colder, H. Urdahl, L. M. Davies, and A. Eastwood. 2004. GeneralisabUity in Economic Evaluation Studies in Health Care A Review and Case Studies. Health Technology Assessment 8(49) (whole... [Pg.313]

Effects Side Effects of Dental Restorative Materials. National Institutes of Health, Technology Assessment Conference Statement. August 26-28, 1991. [Pg.214]

Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1994. Guidelines for Economic Evaluations of Pharmaceuticals. Ottawa, Canada CCOHTA. Available at http // www.ccohta.ca [Accessed November 5, 2005]. [Pg.280]

CCOHTA Canadian Coordinating Office for Health Technology Assessment... [Pg.304]

Eiser, C. and Morse, M. (2001). Quality of Life in chronic diseases of childhood. Health Technology Assess 5(4), 1-157. [Pg.96]

Hoare C, Li Wan Po A and Williams H (2000) Systematic review of treatments for atopic eczema. Health Technology Assessment 4 1-191. [Pg.300]

Petticrew M, Watt I, Sheldon T (1997) Systematic review of the effectiveness of laxatives in the elderly. Health Technology Assessment 1997 1(13). [Pg.410]

Another, more recent, example is enzyme therapy for Gaucher s disease, an inborn error of metabolism, treated with Ceredase. The therapy, which requires more than a ton of placenta annually to extract and make the drug, can cost as much as 500,000 per year per person, depending on the dosage needed. A 1996 National Institutes of Health technology assessment panel addressed issues in diagnosis and treatment of the disease and concluded that despite the success of enzyme therapy, treatment is limited by the cost. [Pg.2473]

Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Macpherson K, Parrott S, Quinn S, Tochel C, Watson H. Prevention of relapse in alcohol dependence. Health Technology Assessment Report 3. Glasgow Health Technology Board for Scotland, 2003. [Pg.2425]

Health technology assessment organizations are the government agencies that apply pharmacoeconomic data to make marketing authorization, pricing, and reimbiirsement decisions. [Pg.190]

The International Network of Agencies for Health Technology Assessment (INAHTA). URL http //www.inahta.org/inahta web/index.asp (accessed October 2005). The INAHTA was... [Pg.190]

Center for Reviews and Dissemination (CRD). University of York, York, U.K. URL http //www.york.ac.uk/inst/crd/ crddatabases.htm (accessed October 2005). CRD aims to provide research-based information about the effects of interventions used in health and social care. It helps to promote the use of research-based knowledge. CRD offers three databases NHS Economic Evaluation Database (NHS EED) Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA) Database. [Pg.191]

Akehurst R, Anderson P, Brazier J, et al. Consensus Conference on Guidelines on Economic Modeling in Health Technology Assessment. Decision analytic modeling in economic evaluation of health technologies A consensus statement. Pharmacoeconomics 2000 17 443M44. [Pg.15]

Includes the Database of Abstracts of Reviews of Effectiveness (DARE), NHS Economic evaluation database, and the Health Technology Assessment (HTA) database... [Pg.30]

Clegg A, Bryant J, Nicholson T et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer s disease. Health Technology Assessment report on behalf of the National Institute for Clinical Excellence (2000). http //www.nice.%20org.uk/... [Pg.148]

National Institutes of Health Technology Assessment Workshop Panel The Persian Gulf experience and health. JAMA 272 391-396, 1994 Newhouse P Neuropsychiatric aspects of chemical warfare, in Contemporary Studies in Combat Psychiatry. Edited by Belenky G. New York, Greenwood Press, 1987, pp 185-202... [Pg.21]

Moorhead JF, Suruda AJ Occipital lobe meningioma in a patient with multiple chemical sensitivities. Am J Ind Med 37 443-446, 2000 Nawab SS, Miller CS, Dale JK, et al Self-reported sensitivity to chemical exposures in five clinical populations and healthy controls. Psychiatry Res 95 67-74, 2000 Perry S Tech-brief from the Alberta Implementation Committee for Health Technology Assessment. Int J Technol Assess Health Care 11 623-639, 1995 Randolph TG Allergy as a causative factor of fatigue, irritability, and behavior problems of children. J Pediatr 31 560-572, 1947... [Pg.282]

Grant AM, Altman DG, Babiker AB, et al. (2005) Issues in data monitoring and interim analysis of trials. Health Technology Assessment 9 1-238, iii-iv. [Pg.65]

Canadian Co-ordinating Office of Health Technology Assessment, Guidelines for the Economic Evaluation of Pharmaceuticals, 2nd edn, Canada, Ottawa, 1997 November. [Pg.74]

M Bradley, N Cullum, T Sheldon. The debridement of chronic wounds a systematic review. Health Technology Assessment 3 (no. 17, part 1 ), 1999. [Pg.99]

National Institutes of Health Technology Assessment Workshop. The Persian Gulf Experience and Health. Bethesda, Md National Institutes of Health 1994. [Pg.195]

Canadian Coordinating Office for Health Technology Assessment 110-955 Green Valley Crescent Ottawa ON K2C3V4 Canada, (613) 226-2553 Website www.ccohta.ca... [Pg.841]

Catalan Agency for Health Technology Assessment Travesserade les Corts 131-159 Pavello Avenue Maria, 08028 Barcelona Spain, (34) 93-227-29-00 Website www.aatm.es... [Pg.841]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...